Animal Models of Parkinson's Disease: Are They Useful or Not? by Barker, Roger & Björklund, Anders
ANIMAL MODELS OF PARKINSON’S DISEASE ARE THEY USEFUL OR NOT? 
 
 
Roger A Barker1 and Anders Björklund2 
1Department of Clinical Neuroscience and WT-MRC Cambridge Stem Cell Institute, Forvie 
Site, Cambridge CB2 0PY, UK  
(email rab46@cam.ac.uk; Tel :+44 1223 331160; Fax +44 1223 331174) 
2Wallenberg Neuroscience Center, Department of Experimental Medical Science, Lund 
University, 22184 Lund, Sweden 





The use of animal models in Parkinson’s Disease research has been controversial in terms of 
how well they relate to the clinical condition and thus their utility for translating therapies 
from the lab to the clinic. In this article two researchers debate this issue with Roger Barker 
taking the view that such models are not useful and may even be misleading while Anders 




Animal models have failed: Roger A Barker 
Parkinson’s Disease (PD) is a uniquely human condition that typically presents late in life and 
is sporadic in origin in the vast majority of cases. The average age at which it is diagnosed 
clinically is about 70 years[1, 2] and it progresses slowly over many years/decades with a 
prodromal stage of disease that may be as long as 10-15 years ahead of the motor 
presentation and diagnosis[3]. It is defined clinically by motor abnormalities (resting tremor, 
bradykinesia and rigidity) as well as an array of non-motor features many of which are 
purely subjective in nature, such as apathy, somnolence and changes in mood and anxiety. 
These latter clinical features are by their very nature human specific but which significantly 
impact on quality of life[4]. All of these clinical features reflect an underlying pathology that 
involves the enteric and autonomic nervous systems as well as sites across the CNS. 
However, the extent of these varies between patients. As such the disease is very 
heterogenous with some patients progressing rapidly to falls and an early dementia, while 
others progress more slowly reflecting a much more benign condition[5].  
Pathologically PD is characterised by the presence of alpha synuclein Lewy bodies and Lewy 
neurites and the loss of the nigrostriatal dopaminergic pathway[6] . However, the disease is 
not restricted to this site pathologically as there is evidence that alpha synuclein pathology 
is found at many CNS sites as well as outside the brain and that this may even be where the 
disease process actually starts[7]. Furthermore, there is now accumulating evidence that all 
chronic neurodegenerative disorders of the brain, of which PD is just one example, are 
characterised by mixed pathologies including vascular disease and other proteinopathies, of 
which one is dominant but not exclusively present, namely alpha synuclein in PD [8].  
All of this creates a major problem when it comes to simulating PD in the laboratory as 
ideally any animal model should include: 
- Aged animals (>18 months old for rats); 
- A slowly progressive disease starting at around 12 months of age in the rat or mouse 
with clear motor features appearing and progressing from about 18 months of age to 
death at 2 years; 
- No genetic manipulation around a single known mendelian gene linked to PD (i.e. 
not in transgenic animals) given most patients do not harbour such mutations; 
- Alpha synuclein pathology in the brain, enteric and autonomic nervous system 
including the development of Lewy bodies and Lewy neurites in the relevant 
neuronal populations at the right time- thus starting in the gut and olfactory bulb 
before spreading up the brainstem and across into the cortices; 
- The range of pathologies seen in patients dying with PD that lie outside those that 
are defined solely by the alpha synucleinopathy; 
- Behavioural deficits that encompass all the features of PD in the right temporal order 
and which recapitulate those found in patients symptomatically; 
- Methods for capturing and assessing the more subjective aspects of PD that greatly 
impact on the quality of life of patients and their carers including apathy, anxiety, 
somnolence etc.  
This has so far not been achieved as most models of PD use young animals that have either 
had been modelled using: 
- Neurotoxins to directly target the dopaminergic nigrostriatal pathway (e.g. 6-OHDA 
and MPTP); 
- The overexpression of a pathogenic protein (e.g. AAV – alpha synuclein) in target 
areas of the brain; 
- Transgenic animals that incorporate one of the known mendelian genes causing 
parkinsonism (e.g. LRRK2 mice); 
- Injections of preformed fibrils (pff) of alpha synuclein to seed pathology across the 
neuroaxis. 
However, it is clear none of these approaches come close to modelling PD in patients. More 
specifically, the neurotoxin models whilst having the merit of allowing one to study the 
dopaminergic system in PD- thus creating a model that has so called face validity (i.e. 
modelling a core pathological deficit of PD- this is not the same as studying the complex 
pathology, clinical expression and temporal progression of what is seen in patients with PD. 
A model capturing this would have construct validity. However, focal injections of alpha 
synuclein while allowing you to study what effect overexpression of alpha synuclein has on 
that region of the brain, this does not tell you what goes wrong in PD where alpha synuclein 
levels are normal. Transgenic models can help tell you about the role of a pathogenic gene 
and its protein product but this is not the same as studying PD given that <5% of patients 
with PD in the community have Mendelian forms of the condition[9]. Finally injections of 
alpha synuclein pff tell you about how this protein can spread and seed pathology as it does 
so, but there is no evidence that this actually happens in the brain of patients with PD[10, 
11] nor that these fibrils resemble those found in the PD brain[10].  
Thus, none of these models recapitulates the age of onset, the temporal speed of the 
disorder nor the spectrum of problems and pathologies you see in the clinic in patients with 
PD. As such these models cannot really help us understand and treat PD in terms of getting 
to the core pathological events in the vast majority of people with sporadic disease. In fact, 
they can be positively misleading as they are modelling the wrong construct!  
This last point is important as it can have a major impact on translation to the clinic. One 
illustration of this is with the growth factor GDNF. This factor was shown to work well in 
rescuing the aging and/or neurotoxin lesioned dopaminergic system in rodents and non-
human primates- but when tried in PD patients it has not worked in a reproducible way 
(reviewed[12] ). Subsequently it was shown when using alpha synuclein as the “toxin” to 
model PD in the lab that this protein could interfere with the signalling pathway of GDNF, 
which could explain the lack of clinical efficacy[13]. However, this was only modelled in the 
lab through overexpression of alpha synuclein, which is not the situation in patients. So 
what can we learn about the therapeutic role of GDNF from this preclinical work for patients 
with PD - not much, only that it can work on acutely lesioned rodent and NHP nigrostriatal 
dopamine neurons to restore their function in vivo. Of course, one could argue that such 
work should only be interpreted when done in conjunction with human in vitro systems. 
Such a system could be one employing patient derived neurons derived from human 
pluripotent stem cells sources - but this system is even further removed from the PD brain 
both in terms of the age of cell being studied and the environment in which they find 
themselves! 
Thus we have to accept that animals can only ever be used to model specific features of the 
pathology of Parkinson’s disease but not the disease itself and as such searching for disease 
modifying therapies in animal models for PD is not a useful exercise. The reason being that if 
you find a therapy that works in some animal model there is no reason to believe it would 
necessarily work in a patient with PD as they represent two totally different disease states. 
Similarly if an agent does not work in an animal model then there is no reason it might not 
work in PD patients, because as we have clearly stated these models do not resemble PD 
clinically. So why waste time studying such imperfect models of disease, rather we should 
be undertaking more experimental medicine studies in PD patients with agents that have 
gone through the relevant safety and biodistribution testing and with a target that should 
be relevant for the disease process based on in vitro mechanistic studies. So, now is the 
time to abandon animal models of PD at least for looking at agents of disease modification! 
Animal models have not failed us: Anders Björklund2  
Can we do without animal models in PD research? Investigators involved in the 
development of new therapies and treatments are rightly concerned about the relevance 
and predictability of disease models for the initiation and design of clinical trials. This 
distrust is understandable given the numerous examples where seemingly convincing 
animal data have not panned out in subsequent clinical trials. The experience from the 
stroke field is particularly disheartening. This is even more disturbing since, in this clinical 
condition the animal models seem as perfect as they can be: the ischemic insults used in the 
animal experiments are identical to the ones seen in patients and should thus have a high 
level of predictability. Nevertheless, there are many cases where an intervention with a 
striking and convincing treatment effect in stroke models has failed when applied to 
patients. These failures have not only been extremely costly for the industry but they have 
also been discouraging and fostered a cynical attitude toward the need of animal models for 
the development of new therapies: If the models are misleading and lack predictability we 
will do better without them. 
In the PD field, however, it is undeniable that studies and findings in animal models have 
played a key role in the development of the therapies that are used today. The development 
of L-DOPA therapy was triggered by observations in reserpine-treated rats and rabbits; the 
development of dopamine receptor agonists was based on studies performed in rodent 
neurotoxin models; and the identification of the subthalamic nucleus for deep-brain 
stimulation (DBS) therapy was critically dependent on the functional analysis of basal 
ganglia circuitry carried out, above all, in MPTP-treated monkeys. 
In the early days, however, the use of the experimental models, and the importance given 
to them, was much more limited than they are today. The development of L-DOPA therapy 
is an interesting example. The justification to initiate trials in patients was essentially based 
on three single observations: The finding that the sedative state induced by the monoamine 
depleting drug reserpine in rats and rabbits could be reversed by a single injection of L-
DOPA, made by Arvid Carlsson and coworkers in 1957[14], followed 2 years later by the 
observation that the bulk of the brain´s dopamine is located in the striatum[15], and a year 
later by Oleh Hornykiewics´ finding that dopamine is markedly and consistently reduced in 
the caudate nucleus and putamen of Parkinsonian patients[16]. The first open label trial of 
L-DOPA in PD patients were initiated in 1961-62, within less than 5 years of the initial animal 
experiment[17, 18].  The development of a clinically useful therapy took another 5 years, 
marked by the publication of George Cotzias´ landmark paper in NEJM in 1967[19]. It is 
indeed remarkable that this “fast-track” approach is how limited animal experiments were 
used in some of the early clinical breakthroughs in medicine, such as the introduction of 
insulin therapy in the 1920s and the development of penicillin in the 1940s.    
All this took place before the now commonly used neurotoxin models had been introduced. 
The reserpinized rats and rabbits used in the initial Carlsson et al. experiment can hardly 
qualify as a model of PD: Reserpine depletes not only dopamine but also noradrenaline and 
serotonin, and the immobility seen in these animals is confounded by a general sedative 
state. The unilateral 6-OHDA lesion model is the first one to replicate a central aspect of the 
pathophysiology of the disease, i.e. the degeneration of the midbrain dopamine projection. 
This model with its face validity for modeling PD was developed in 1968[20], and it is 
interesting to consider that if Arvid Carlsson had made his first L-DOPA experiments in 6-
OHDA lesioned rats the drug may never had reached the clinic. This is because in this model, 
where the 6-OHDA is injected into the medial forebrain bundle (MFB) on one side, the 
therapeutic window of L-DOPA is very narrow. We know today that reduction of the 
hypokinetic symptoms in the absence of dyskinesia is seen only with very low doses, 6-8 
mg/kg. At this dose the improvement is only partial, and increases above this threshold 
induces dyskinesia. Even worse, repeated administration of the therapeutic dose over just a 
few days is accompanied by a gradual emergence of dyskinesia that becomes worse over 
time[21, 22]. Confronted with such data it is easy to imagine that the early investigators 
would have been scared off and that the implementation of L-DOPA therapy in the clinic 
would not have happened or at least been seriously delayed. Thus, the choice of the model 
may be critically important: In this case it would have been a mistake to use the standard 
MFB lesion model where the striatum is completely denervated of its dopamine input, since 
the ability of L-DOPA to improve the motor features in the absence of dyskinesia depends 
on the presence of a spared dopamine innervation, sufficient to buffer the swings in L-DOPA 
derived dopamine caused by the intermittent drug delivery. Partial 6-OHDA lesions, or 
MPTP lesioned mice, i.e. models that were developed decades later, would thus be a more 
suitable choice in this case.     
Until the turn of the millennium experimentalists were largely satisfied with the models they 
had at their disposal. The neurotoxin models had served us well, and we could also claim 
that they had proved their value for the development and improvement of PD therapy, the 
introduction of a broad range of dopaminergic drugs and DBS in particular. During the last 
two decades this has all changed. Since then, there has been a gradual shift of emphasis 
from treatment of symptoms to the search for protective and disease-modifying therapies, 
and a concomitant shift away from the classical view of PD as a dopamine deficiency 
syndrome to the idea of a more widespread and system-encompassing disorder where the 
main culprit, α-synuclein, is caused to aggregate and spread and interact with the immune 
system. The main trigger of this change was the discovery of the role of α-synuclein in the 
pathogenesis in 1997[23, 24] and the gradual realization that PD belongs to the category of 
protein misfolding disorders with an onset that may start long before the classic motor 
symptoms occur.  
These developments present a serious challenge to the disease modelling field. The studies 
of the familial forms of the disease, in particular, have shown that clinical conditions 
classified as PD can have quite different causes, and driven by different molecular and 
genetic mechanisms. As a result, there is now a general consensus that PD is not a single 
disease entity, but comprises different subtypes reflected in differences in the spectrum of 
symptoms and the nature and distribution of Lewy body pathology. Disease modelling has 
had to adapt to this changing scenery. A single model modality will no longer suffice, and 
the neurotoxin models, though still highly useful, must be complemented with models that 
more closely replicate the disease pathology and its progression- namely the development 
of models that have construct validity.  
The multitude of animal models available to us today is very broad, ranging from worms and 
flies to rodents and primates. While studies in worms and flies can be useful as tools to 
explore individual pathogenic pathways, and for high-throughput genetic screens, in 
particular[25] we need to resort to rodents and non-human primates in order to get closer 
to the human disease with Lewy body pathology and progressive nigrostriatal degeneration 
at the core. In many cases the rodent models have been developed, not to replicate all 
aspects of the disease, but to model selected, interacting pathways, such as mitochondrial 
dysfunction and damage, α -synuclein aggregation and spread, impaired degradation of 
misfolded proteins, or activation of the innate immune system[26, 27]. This diversity of 
models is valuable in that they allow for a reductionist, hypothesis-driven approach to the 
identification and exploration of potential therapeutic targets, and are thus indispensable 
for any serious pre-clinical research in the PD field. All of them have limitations and none of 
them recapitulate all the pathologic and behavioral phenotypes of PD, but carefully selected 
they are complementary and can be used in parallel to add strength to a preclinical data 
packet. 
The α-synuclein based rodent models – genetic or induced – are probably the ones that 
come closest to a replication of progressive PD-like pathology. They are attractive and useful 
in that the extent of Lewy body-like pathology can be modified so that it is confined either 
to the midbrain dopamine system (such as in the intranigral AAV-alpha-synuclein and/or PFF 
models), or expanded to resemble a more generalized alpha synucleinopathy, akin to Lewy 
Body Dementia (LBD) (such as is the case in some of the transgenic mouse models). It may 
be argued, of course, that the predictive value of these models is as yet unproven. That is 
true, but depending on how the models are used they offer valuable opportunities to 
explore potential therapeutic targets in a designed and hypothesis-driven manner. In 
studies aimed to prevent the aggregation of α-synuclein, or remove α-synuclein aggregates, 
for example, the models we have would be ideal to assess the efficacy of antibodies or other 
potential therapeutic agents, similar to the pre-clinical studies in APP expressing transgenic 
mice that preceded the clinical trials of amyloid antibodies in Alzheimer´s disease. Although 
the clinical benefit of this treatment remains unclear, the elimination of amyloid plaques in 
the mouse models has been nicely replicated in AD patients, confirming the predictive value 
of the models in this case. 
Properly used, the currently available animal models are indispensable for the development 
of new concepts and ideas that can lead to novel protective or disease-modifying therapies. 
It is difficult to imagine how the development of novel therapies for PD could be achieved 
without animal models. It is argued that they are expensive and time-consuming and, if 
unreliable, a waste of both time and resources. For ethical reasons, however, we cannot 
avoid using them as an essential part of the pre-clinical testing if we want to ensure that the 
trials are performed on a scientifically sound basis. The possibility to establish “target 
engagement” in in vitro models and then move directly to trials in humans could have been 
possible 50 years ago, but would be far too risky to be acceptable today. Similarly, the 
“quick and daring” approach used in the early days when clinical trials could be initiated 
based on a single symptom-reversal experiment performed in a just a few animals, as in the 
development of L-DOPA therapy in the 1960s, is no longer an option. Current efforts to 
replicate PD-related pathology in vitro in patient-derived induced pluripotent stem cells 
(iPSCs) and organoid cultures[28] offer interesting possibilities to speed-up drug screening 
and assist in the development of new treatment concepts. These novel tools may in the 
future help to reduce, but cannot replace, the need of pre-clinical data generated in 
relevant animal models.  
So, if animal models are indispensable, the challenges remain: which model to choose, how 
to apply it to the question being posed and how to interpret the results. We have to accept 
that there is no single animal model that can be applied in all cases. A scientific approach to 
therapy development says that we need to be hypothesis-driven and reductionist in our 
thinking and choose the model that best matches our need to prove or disprove the 
underlying mechanistic hypothesis. At the same time we should be aware that the models 
we use may have to be adapted to match different disease subtypes. Thus, the development 
of increasingly more refined animal models needs to go hand-in-hand with the increasing 
insights into the pathogenic mechanisms that characterize and distinguish different PD 
subtypes and alpha-synucleinopathies.  
   
Rebuttal from Roger A Barker 
In his defence of the usefulness of animal models for studying Parkinson’s Disease (PD), 
Anders Björklund lays out the history of how such models came into existence and their 
utility over the years. This includes an illuminating discussion on how L-dopa came into 
clinical use in PD despite very limited preclinical work in flawed animal models. Indeed the 
critical work showing the value of this whole approach came from early experimental 
medicine trials in patients. These trials initially showed no benefit for this agent in PD[29], 
but through an iterative process this therapeutic turned into, and has remained, the 
mainstay of managing PD. Thus we can see that the single biggest breakthrough in the 
treatment of PD was essentially done independently of any animal models. 
Anders then shows how for the next 30 or more years the models of PD concentrated on 
the nigrostriatal dopaminergic pathway with the hope that this would lead to new therapies 
and breakthroughs in PD. None came and the therapeutic advances during this time were 
achieved through the pharmaceutical industry looking at different agents working on 
dopamine receptors and its catabolism. Arguably these dopaminergic centric models for PD 
did support the use of deep brain stimulation in the 1990s which followed on from lesion 
studies in patients in the 1980s. While there is no doubt that such preclinical work gave a 
scientific basis to what was being done and refined the procedure, much of the pioneering 
work supporting this whole approach  came from work done on patients in the 1950s[30] 
before any animal models for PD even existed. 
In this century, animal models have turned more to using the protein that lies at the heart 
of PD- alpha synuclein. The use of these alpha synuclein models has helped us understand 
some aspects of the behaviour of this protein- and both myself and Anders agree on this-  
but the critical question remains; has this helped us understand PD better? This is perhaps 
where we differ most and the very case that Anders cites in favour of this, I would say 
argues the opposite- namely the immune therapies targeting Aβ amyloid in Alzheimer’s 
disease (AD).   In this work, it was clearly shown that transgenic animals overexpressing this 
protein could develop the amyloid pathology of AD and this could be effectively removed by 
immune therapies targeting this protein. This has led to numerous studies showing that this 
occurs in patients dying with AD, but that this makes no significant difference to their 
clinical course or outcome[31]. In other words, the animal model using a reductionist 
approach for AD failed to recapitulate the problems in patients with AD and subsequently 
billions of dollars has been spent pursuing this flawed hypothesis[32]. The question is, do we 
really want to do the same in PD? 
So I come back to where I began in my initial arguments against using animal models for PD 
to predict clinical effects and therapies. Namely I would advocate that more targeted 
iterative experimental medicine approaches are now needed to better treat PD just as was 
done in the 1960s! 
 Rebuttal from Anders Björklund 
Roger Barker summarizes well the limitations of current models of PD and suggests that we 
should, rather than wasting time on imperfect animal modelling, focus on experimental 
studies in PD patients using agents of known safety and with relevant targets based on in 
vitro mechanistic studies. Although I agree with Roger that the PD models available today 
can only be used to model specific features of the disease but not the disease itself, I would 
argue that this is in fact their strength and makes them ideally suited for hypothesis driven 
reductionist approaches to the development of new drugs and other interventionist 
treatments.  The classic neurotoxin models, for example, have proved highly valuable for 
the development of drugs aimed at treatment of the symptoms related to the core 
pathology of PD, DA neuron loss, and will undoubtedly remain the preferred tools for pre-
clinical validation of such treatments in the future. This is also true for the development of 
restorative therapies, such as dopamine cell replacement or gene based therapies that seek 
to restore function without modifying the underlying disease.  
Findings in these classic models can of course be misleading, and Roger uses the failure of 
the GDNF trials as a discouraging example. To this, I would argue that the lack of success of 
GDNF in the patient trials may not be due to shortcomings of the pre-clinical models – they 
have been very useful as tools to characterize the mode of action and therapeutic promise 
of this factor – but rather linked to how, where and when the factor is given to the patients. 
In this case I don´t think the last word has been said yet!  
The challenge is the modelling of the progressive disease processes seen in the various 
forms of PD, i.e. the kind of models needed for the development of disease modifying 
therapies. Here, the study of the familial cases have been important and lead to the 
identification of the major players in the pathogenic process: mitochondrial dysfunction and 
oxidative stress; alpha-synuclein misfolding and spread; dysfunction in the protein handling 
and clearance systems; and immune/inflammatory mechanisms. This has led to the 
development of a new generation of PD models and given us new powerful experimental 
tools to identify potential therapeutic targets that allow us to interfere at distinct stages of 
the disease[33]. This has also given us tools to model pathogenic subtypes related to 
differences in the induction and spread of alpha-synuclein-related pathology, such as, for 
example, the brainstem-predominant and limbic-predominant pathologies described by the 
Arizona PD Consortium[34], the gut-to-brain transfer of pathology[35], and the “PNS-first” 
and “CNS-first” subtypes defined by Borghammer and Van Den Berge[36]. 
If we don´t want to depend on pure luck, the way forward is the classic hypothesis-driven 
reductionist approach. The strength of the new generation of PD models is that they allow 
us to focus in on selected targets that play a key role in disease progression and propagation 
of disease pathology, linked to different disease subtypes, and thus open up for discoveries 
that are transformative rather than incremental. The access to models that replicate the 
initiation of distinctive disease processes and their alternative routes of spreading and 
propagation are very attractive and can be effectively used for pre-clinical validation of 
novel therapeutic targets, leading to their further exploration in the “real” disease in 
patients. This kind of hypothesis-driven approach is in no way in conflict with Roger´s idea to 
undertake more experimental medicine based studies aimed at the repurposing of known 
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